Beyond being a regulatory checkbox, patient diversity is a critical factor in developing safer, more effective medical treatments for everyone.  

When diversity is missing, the consequences are concrete and sometimes severe: 

• Safety signals get missed. Adverse events that show up only in specific populations may go undetected until after a drug reaches the market. 

• Efficacy becomes unpredictable. A drug proven effective in one group might not work as well, or at all, in another.  

• Dosing gets risky. Without understanding how metabolism varies across populations, we risk under- or overdosing patients.  

When clinical trials include people of diverse backgrounds, researchers gain a much clearer picture of how drugs perform in the real world[1]. This leads to more accurate dosing, fewer unexpected side effects, and better treatment outcomes across the board. 

Of course, clinical studies can be conducted on a more uniform population, but if inclusion and exclusion criteria for your work are not well-defined[2], there is a risk of producing results that don’t hold up beyond that narrow group. The study may look sound on paper, but the findings might not translate once they are tested[3]in broader, more varied populations.  

How Diverse Are Clinical Trials Today? 

Historically, most clinical trials have drawn data from a narrow slice of the global population[4] — mainly younger, white males from high-income countries. In many trial datasets, approximately 73% of participants are white, and 62% are male[5][6]. That means large parts of the world, including  Asia, Africa, and Latin America[7], have been left out of the evidence base that informs how treatments are approved and prescribed. Even when trials do reach low- and middle-income countries (LMICs), they’re often limited to major cities or select hospitals, excluding rural and lower-income communities[8][9].   

Diversity in trials must be understood in broad terms, encompassing race and ethnicity, age, sex and gender, socioeconomic status, geographic region, comorbidities, and exposure to different environmental and cultural factors[10]. Each of these dimensions can influence how a drug metabolizes, whether side effects appear, and how likely someone is to adhere to the treatment. 

Women, older adults, and people from underrepresented communities are routinely left out, despite often carrying the highest disease burden. Data shows median female enrollment rates around 41% across randomized controlled trials, and the oldest age groups (for example, those ≥80) often have participation rates far below their prevalence in disease populations[11][12].  

These oversights have led to post-market dose adjustments, boxed warnings, and, in worst cases, market withdrawals when real-world use revealed unacceptable harms in overlooked groups[13][14]. 

Thankfully, regulators and international bodies are pushing for change. The U.S. FDA, the European Medicines Agency, and the WHO now expect sponsors to enroll more diverse populations, and even require Diversity Action Plans for certain studies[15][16]. In Asia and Southeast Asia, regulatory agencies are following suit[17][18][19] which is strengthening guidance on ethical enrollment, data transparency, and global harmonization through frameworks aligned with ICH-GCP. These shifts signal that inclusive research is an essential step to conducting a full-scale study.  

How Clinical Trial Diversity Improves Safety Profiles and Treatment Outcomes Worldwide 

Inclusive trials give sponsors a much stronger foundation for decision-making[20][21]. With broader data, healthcare providers make more confident treatment decisions that extend to a wider range of patients, and not just narrow subgroups. 

Here’s how diversity improves trial outcomes across the board: 

1. Stronger safety and efficacy insights

People process medications differently, and genetics often play a big role. For example, variations in enzymes like CYP2D6 or CYP3A4 can significantly affect how drugs are absorbed or metabolized. When those populations are left out of trials, researchers risk: 

• Missing critical safety signals 

• Overlooking subgroup-specific side effects 

• Approving doses that are ineffective or harmful for some groups 

Inclusive research helps identify these nuances early, leading to better-designed therapies and fewer post-approval surprises such as dose adjustments, warnings, or withdrawals. 

2. Reduced gaps between trial and real-world results

Trials often rely heavily on young, healthy, urban participants. But what happens when those same drugs are used by older adults, people with multiple conditions, or those living in different environments? 

Diverse trials help minimize the gap between expected outcomes and real-world performance[22][23] by: 

• Proactively addressing variability before launch 

• Creating more stable and predictable treatment results 

• Reducing long-term healthcare risks for patients and providers 

3. Faster regulatory approvals and market entry

Regulatory agencies around the world, including the FDA, EMA, and WHO, are raising the bar on diversity. Trials that demonstrate inclusive design from the start are more likely to: 

• Skip additional bridging studies 

• Avoid post-market commitments 

• Get approved faster, especially in Asia, Africa, and Latin America 

This translates to lower development costs, quicker timelines, and earlier access for patients who need new treatments most. 

4. Greater credibility and brand trust

Trust matters, most especially and critically in healthcare. Inclusive trial practices convey a clear message: we care about equity, transparency, and patient-centered innovation. That can lead to: 

• Stronger relationships with regulators, clinicians, and ethics boards 

• More successful patient recruitment and site engagement 

• Increased goodwill from investors and patient communities alike[24]. 

5. A healthier global impact

The long-term benefits are clear. When clinical research is inclusive: 

• Patients feel seen, heard, and safer engaging in medical systems 

• Providers have data they can confidently apply to personalized care 

• Regulators can make decisions based on globally relevant evidence 

Ultimately, inclusive trials don’t just improve individual products, they raise the standard of care for everyone, everywhere. 

How Southeast Asia Can Strengthen Clinical Trial Outcomes 

Southeast Asia, home to 676.6 million people and the world’s third-most populous region[25], represents one of the most diverse yet underrepresented populations in global clinical research.Including Southeast Asian populations, particularly the Philippines, is essential to ensure that new treatments are tested, validated, and optimized for the real-world diversity they aim to serve. The region plays an outsized role in global health, and here’s why it matters: 

• Demographic and ethnic diversity. Southeast Asia hosts a richly varied mix of ethnicities, health-profiles, and environmental exposures. Including these groups gives us a more accurate picture of how therapies work in the real world. 

• Under-representation is real. Recent research into trials across Asia found that while ~46% of Phase 2/3 oncology trials had sites in Asia, much of that participation comes from East Asia (e.g., China, Japan, South Korea), and many Asian countries (including those in Southeast Asia) remain significantly under-represented.[26][27]  

• Operational readiness and alignment. The Philippines offers treatment-naïve populations, a healthcare system aligned with international standards, and strong English proficiency — all of which make it a strategic choice for inclusive clinical research. 

• High disease burden + unmet need. Many conditions that are prevalent in Southeast Asia may not be sufficiently studied in trials dominated by Western populations. Including the region helps ensure treatments are safe and effective for those who bear the burden. 

• Better science, better outcomes. When trials include varied populations: 

• Safety data become richer and more reliable across sub-populations. 

• Efficacy predictions improve because they account for different backgrounds. 

• Dosing strategies become more tailored rather than based on assumptions. 

• Patient trust rises when communities see themselves represented in research. 

That’s where the Philippines comes in.  

With its diverse population comprising treatment-naïve patients with a healthcare system aligned with international standards, the Philippines offers a unique opportunity to run inclusive, high-quality studies that reflect real-world complexity. It’s a promising, strategic location for sponsors who want their trials to deliver on safety, efficacy, and equity. 

As the pharmaceutical and clinical research fields continue to pursue faster, more precise, and more patient-centered drug development, inclusive research is foundational. In Southeast Asia, and in the Philippines, the next generation of breakthrough clinical trials will start with who’s in the room, not just what’s in the protocol. 

Work with PiVOT: Your Trusted CRO Partner for Clinical Trials in the Philippines 

As the pioneering Filipino Contract Research Organization (CRO) with global alignment, PiVOT delivers the reach, richness, and operational readiness needed for success. With a strong network of high-performing sites, proven patient recruitment capabilities, ICH-GCP–trained teams, and full end-to-end operational support, PiVOT is uniquely positioned to drive trial excellence from start to finish. 

Start in the Philippines. Start with PiVOT.